Sophia Genetics (Sophia Genetics) Debt-to-Asset : 0.10 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Sophia Genetics Debt-to-Asset?

Sophia Genetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.70 Mil. Sophia Genetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.74 Mil. Sophia Genetics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $180.26 Mil. Sophia Genetics's debt to asset for the quarter that ended in Mar. 2024 was 0.10.

Sophia Genetics Debt-to-Asset Historical Data

The historical data trend for Sophia Genetics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sophia Genetics Debt-to-Asset Chart

Sophia Genetics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.16

0.06

0.04

0.07

0.09

Sophia Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													0.08	0.09	0.09	0.09	0.10

Competitive Comparison of Sophia Genetics's Debt-to-Asset

For the Health Information Services subindustry, Sophia Genetics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sophia Genetics's Debt-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sophia Genetics's Debt-to-Asset falls into.

Sophia Genetics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sophia Genetics's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.928	+	15.673)	/	206.156
	=	0.09

Sophia Genetics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(2.704	+	14.738)	/	180.258
	=	0.10

Sophia Genetics (NAS:SOPH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sophia Genetics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sophia Genetics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sophia Genetics (Sophia Genetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Sophia Genetics SA (NAS:SOPH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

90B:Germany

Address

Rue du Centre 172, Saint-Sulpice, CHE, CH-1025

Website

https://www.sophiagenetics.com

Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.